Eli Lilly filed lawsuits against six companies for selling retatrutide to consumers. Retatrutide is an experimental obesity drug. It has not been approved by the FDA. It remains in clinical trials. The companies sold it anyway.
Someone looked at a drug that exists only in testing facilities and thought "I should monetize this." Then they built entire businesses around hawking a pharmaceutical product that regulatory agencies have explicitly not cleared for human consumption outside controlled studies. The confidence required to sell unapproved weight loss medication to strangers on the internet deserves some kind of recognition. Not a positive kind. But some kind.
Lilly spent years and hundreds of millions developing retatrutide through proper clinical channels. These six companies skipped that part. They just started selling it. No safety data. No long-term studies. No legal approval. Just vibes and a Shopify storefront.
The lawsuit targets businesses that marketed retatrutide products despite the drug being under clinical development. Lilly wants them to stop. The companies probably will not stop voluntarily because stopping would require acknowledging that laws apply to them. That's a tough pill to swallow. Unlike retatrutide, which apparently goes down easy if you buy it from the right unregulated vendor.
Retail traders will see this headline and immediately check if Lilly stock moved. It didn't. They will then search for tickers of the six defendant companies. Those don't exist. They will feel confused and betrayed. This is called learning.
The defendants sold a product that hasn't passed clinical trials to customers who didn't ask whether it passed clinical trials. It's a perfect marriage of supply-side fraud and demand-side desperation. Lilly is suing to protect its intellectual property rights and also probably because watching people sell your unfinished drug feels like watching someone else wear your skin.
Photo by on Unsplash
Leave a Comment